Bicycle Therapeutics
Therapeutics based on its proprietary bicyclic peptide product platform.
HQ location
Cambridge, United Kingdom
Website
Launch date
Employees
Market cap
$501m
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | $555m | Post IPO Equity | |
| Total Funding | 000k | ||
Astellas Venture(exited)
Atlas Venture(exited)
SR One(exited)
SV Health Investors(exited)
Innovate UK(exited)
Eurostars SME programme(exited)
University of Cambridge(exited)
Venture Kick(exited)
Ahren Innovation Capital(exited)
Hercules Capital(exited)
Novartis Venture Fund(exited)
Vertex Ventures HC(exited)
VentureLab(exited)
Cambridge Innovation Capital(exited)
Longwood Fund(exited)
EPFL(exited)
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (25 %) | 13 % | 24 % | 87 % | 31 % | 5 % | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (494 %) | (560 %) | (767 %) | (626 %) | (463 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (491 %) | (571 %) | (779 %) | (670 %) | (479 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 319 % | 384 % | 564 % | 580 % | 490 % | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.